Adamas Pharmaceuticals Inc (NASDAQ:ADMS) Receives $20.86 Average PT from Analysts

Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have earned a consensus recommendation of “Hold” from the eleven brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.86.

A number of research analysts recently issued reports on ADMS shares. ValuEngine downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. HC Wainwright reduced their price target on Adamas Pharmaceuticals from $40.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, May 28th. Finally, Mizuho restated a “sell” rating and set a $5.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday, April 24th.

A number of large investors have recently made changes to their positions in ADMS. BNP Paribas Arbitrage SA purchased a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $33,000. PNC Financial Services Group Inc. purchased a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $43,000. Advisor Group Inc. increased its holdings in Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 4,510 shares during the period. Creative Planning purchased a new position in Adamas Pharmaceuticals during the 1st quarter valued at about $144,000. Finally, Barclays PLC increased its holdings in Adamas Pharmaceuticals by 87.6% during the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after purchasing an additional 8,118 shares during the period. Institutional investors own 76.58% of the company’s stock.

Shares of NASDAQ ADMS traded up $0.07 during midday trading on Wednesday, reaching $6.26. The company had a trading volume of 393,500 shares, compared to its average volume of 459,060. Adamas Pharmaceuticals has a one year low of $4.20 and a one year high of $29.49. The company has a debt-to-equity ratio of 2.00, a quick ratio of 6.86 and a current ratio of 7.03. The company’s fifty day simple moving average is $5.70. The company has a market cap of $178.39 million, a PE ratio of -1.29 and a beta of 1.72.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. The company had revenue of $11.67 million during the quarter, compared to analyst estimates of $12.78 million. As a group, research analysts anticipate that Adamas Pharmaceuticals will post -3.79 earnings per share for the current fiscal year.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Read More: How is diluted EPS different from basic EPS?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.